Breast Neoplasms Clinical Trials in Los Angeles, California

9 studies are recruiting for breast neoplasms in Los Angeles, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

   This is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatment group. This trial will be double-blinded, which means neither the participants nor the trial doctors will know which of the two treatment…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Cedar Sinai - Samuel Oschin Cancer Center, Los Angeles, California

   Locations

   202 in total

   Run by

   BioNTech SE

   See if you can join NCT07173751 on ClinicalTrials.gov

2. A Study of Breast Cancer Risk Factors and Outcomes of People in Florida

   The purpose of this study is to understand why different people have different risks and outcomes for breast cancer and non-breast cancer.

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of California, Los Angeles (Specimen Analysis only), Los Angeles, California

   Locations

   3 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT06780176 on ClinicalTrials.gov

3. Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

   This is a multi-site, global, open-label study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER-2) negative breast cancer. Phase 1b was design…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   California Research Institute, Los Angeles, California

   Locations

   86 in total

   Run by

   Stemline Therapeutics, Inc.

   See if you can join NCT05386108 on ClinicalTrials.gov

4. A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

   The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Participants can remain…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   USC/Norris Comprehensive Cancer Center, Los Angeles, California

   Locations

   360 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07174336 on ClinicalTrials.gov

5. A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

   This study will include two groups of patients: Cohort 1 and Cohort 2. Cohort 1: will help researchers learn how a medicine called imlunestrant (LY3484356) affects a specific type of breast cancer. Some patients will take both imlunestrant and another treatment to suppress their ovarian function. S…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   USC/Norris Comprehensive Cancer Center, Los Angeles, California

   Locations

   89 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07287098 on ClinicalTrials.gov

6. A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

   Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic. * HR positive (HR+) means the cancer cells have proteins that attach to estr…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Los Angeles Hematology Oncology Medical Group ( Site 0026), Los Angeles, California

   Locations

   199 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT07060807 on ClinicalTrials.gov

7. A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

   The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine) fo…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   USC/Norris Comprehensive Cancer Center, Los Angeles, California

   Locations

   295 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT06926868 on ClinicalTrials.gov

8. A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

   This is a global extension study to provide continued access to niraparib and further characterize the long-term safety of niraparib treatment in participants who are currently receiving treatment with niraparib within GlaxoSmithKline/TESARO-sponsored studies (NCT01847274, NCT02354586, NCT01905592,…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   GSK Investigational Site, Los Angeles, California

   Locations

   25 in total

   Run by

   GlaxoSmithKline

   See if you can join NCT04641247 on ClinicalTrials.gov

9. I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

   The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic res…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Southern California, Los Angeles, California

   Locations

   42 in total

   Run by

   QuantumLeap Healthcare Collaborative

   See if you can join NCT01042379 on ClinicalTrials.gov